Eckert & Ziegler

from Wikipedia, the free encyclopedia
Eckert & Ziegler Radiation and Medical Technology AG

logo
legal form Corporation
ISIN DE0005659700
founding 1997
Seat Berlin , GermanyGermanyGermany 
management
Number of employees 825
sales 178.6 million euros (2019)
Branch Medical technology and pharmacy
Website www.ezag.de
As of May 18, 2020

The Eckert & Ziegler Strahlen- und Medizintechnik AG develops and produces isotope technology components for the medical, scientific and metrological applications. The company employed 825 people at the end of 2019. Group sales in the 2019 financial year amounted to € 178.6 million. The company's share has been part of the SDAX since June 24, 2019 and has also been part of the TecDAX of Deutsche Börse since May 8, 2020 .

The main areas of application for the group’s products are medical technology, in particular cancer therapy , nuclear medicine imaging, radiopharmaceuticals and industrial measurement technology. In the medical field, Eckert & Ziegler and its subsidiaries primarily address radiation therapists ( radiation oncologists) and nuclear medicine specialists .

Another company focus is on the disposal of low to medium level radioactive waste.

history

The origins of Eckert & Ziegler go back to the Central Institute for Isotope Technology , a research institute of the former Academy of Sciences of the GDR . After the fall of the Wall, Jürgen Ziegler, a former employee of the Institute for Applied Isotope Research, and Andreas Eckert founded BEBIG Isotopentechnik und Umweltdiagnostik GmbH in 1992. They took over the premises and patents from the winding up of the institute and began producing low-level radioactive radiation sources for industrial and medical applications. In the first official business year of 1994, the new company made 253,000 Deutschmarks in sales.

BEBIG GmbH is now a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG, which was founded in July 1997 as a holding company. The company has been listed on the stock exchange since 1999.

In 2008, Eckert & Ziegler was awarded the prize in the Grand Prize for SMEs .

In 2009 Eckert & Ziegler took over the Braunschweig isotope specialist Nuclitec GmbH. The biggest competitor of yore now operates as Eckert & Ziegler Nuclitec GmbH. At the company's location in Braunschweig, isotope residues with low activity, for example from hospitals and research institutions, are taken back.

In 2012 Eckert & Ziegler founded the subsidiary Eckert & Ziegler BEBIG Ltda. in Fortaleza, Brazil .

In 2014 Eckert & Ziegler founded the subsidiary Eckert & Ziegler BEBIG India Pvt. Limited based in New Delhi, India. Other subsidiaries are Eckert & Ziegler Radiopharma GmbH and Eckert & Ziegler Isotope Products Holdings GmbH.

Business results

Corporate headquarters on the Berlin-Buch campus , Robert-Rössle-Strasse 10

Eckert & Ziegler is one of the suppliers of isotope components for medical, scientific and measurement purposes in the field of cancer therapy, nuclear medicine diagnostics and industrial radiometry.

The company operates worldwide. Group sales in the 2019 financial year were EUR 178.6 million.

With sales of 110.9 million euros in 2019, the largest group division, "Isotope Products", comprises the production of radiation sources for imaging processes, measurements and analyzes, quality assurance and environmental monitoring. The portfolio ranges from calibration sources for PET cameras in hospitals to radiation sources for radiometric level measurements. In 2017, the company took over major parts of the Saxon Gamma Service Group, including a manufacturer of blood irradiation devices, a specialist in the construction of laboratory and handling equipment, and a manufacturer of industrial radiation sources.

The “Radiopharma” and “Radiation Therapy” areas have been merged and have been part of the new “Medical” segment since January 2020.

In the “Radiopharma” division, sales in 2019 were EUR 42.5 million. The products of the “Radiopharma” segment include devices for radiosynthesis and quality control as well as radiopharmaceuticals for the diagnosis and treatment of cancer. Another product in the segment are longer-lived radioisotopes for pharmaceutical applications. This substance is used, among other things, for the production of radioembolizators for the treatment of liver tumors.

The “Radiation Therapy” segment, which includes products for radiation therapy, especially for brachytherapy , generated sales of EUR 30.1 million in 2019. The products are aimed at radiation therapists, a group of doctors who specialize in the treatment of cancer through radiation. The products include radioactive small implants for the treatment of prostate cancer, so-called "seeds", tumor radiation devices, so-called "afterloaders" and eye applicators for the treatment of choroidal melanoma (eye cancer). With the takeover of the Thuringian WOLF-Medizintechnik GmbH, the portfolio was also expanded to include X-ray therapy devices for the treatment of superficial skin tumors and joint diseases.

One of the group's specialties are tumor radiation devices based on cobalt -60 sources. In contrast to the previously prevalent Iridium 192 technology, Cobalt 60 devices have particularly low operating costs with the same treatment effectiveness. In many emerging countries, they therefore form the backbone of basic oncological care or are the first devices of this type in the respective countries, mostly to be found in the central hospitals of the capital cities.

In Africa, Asia and Latin America around 300 clinics are equipped with devices from Eckert & Ziegler AG, which corresponds to a capacity of around 100,000 tumor patients per year. Implants for the treatment of prostate cancer are mainly exported to the countries of the European Union and other industrialized countries for patient numbers of a similar magnitude. Revenues from taking back radiation sources and other low-level waste account for less than 2 million euros. The volume of waste taken back has been falling for years.

Web links

Individual evidence

  1. ↑ a b c d e Eckert & Ziegler Strahlen- und Medizintechnik AG: Annual Report 2019 (PDF) Accessed April 15, 2019 .
  2. ↑ Eckert & Ziegler is included in the SDax. November 23, 2016, accessed June 24, 2019 .
  3. ^ History. September 9, 2017, accessed April 15, 2019 .
  4. ^ Daniel Kastner, Bird of Paradise and physicist, Berliner Zeitung, June 25, 2009.
  5. ↑ A bright future through medical innovations, Süddeutsche Zeitung, May 19, 1999.
  6. ↑ Steffen Uhlmann, “We also grow in the crisis”, Süddeutsche Zeitung, November 5, 2009.
  7. ^ OPS Netzwerk GmbH Germany: Eckert & Ziegler Radiation and Medical Technology AG. Retrieved April 15, 2019 .
  8. ↑ Peter Bloed, Jens Jüttner: Die Zeitwende, Focus Money, June 22, 2011.
  9. ↑ Eckert & Ziegler BEBIG founds subsidiary in Brazil. November 23, 2016, accessed November 28, 2019 .
  10. ↑ ECKERT & ZIEGLER BEBIG INDIA PRIVATE LIMITED | Indian Company Info. In: www.indiancompany.info. Retrieved November 29, 2019 .
  11. ↑ Annual Report 2016. In: ezag.com. Retrieved April 15, 2019 .
  12. ↑ a b c d e Eckert & Ziegler Strahlen- und Medizintechnik AG: Eckert & Ziegler Annual Report 2019
  13. ↑ Eckert & Ziegler plans to take over Gamma-Service. November 23, 2016, accessed April 15, 2019 .
  14. ↑ Strong nine-month numbers. Confirmation of the annual forecast. Merger of the medical divisions from 2020. In: ezag.com. November 12, 2019, accessed May 20, 2020 .
  15. ↑ Eckert & Ziegler buys manufacturer of X-ray therapy devices. November 23, 2016, accessed April 15, 2019 .
  16. ↑ Eckert & Ziegler Strahlen- und Medizintechnik AG: Press release from August 4, 2014, archive link ( memento of the original from April 26, 2016 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / www.ezag.com
  17. ↑ Annual Report 2014. In: ezag.com. Retrieved April 15, 2019 .